Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Cybersecurity Again In Spotlight As Hackers Breach CBER’s Database

This article was originally published in The Pink Sheet Daily

Executive Summary

A hacker gained access to information from about 14,000 users of CBER’s submission systems during the government shutdown.

You may also be interested in...

FDA's Information Security Fixes Expected To Be Completed Within A Year

GAO report prompts vigorous action – and some defensiveness – by the agency.

FDA Cybersecurity Efforts Emphasize Collaboration With Homeland Security Officials, Hospitals

CDRH’s emergency preparedness director spelled out the device center’s cybersecurity efforts during a recent webinar. The efforts go beyond guidance and regulations and include proactive steps to tackle the challenge, including weekly meetings with the Department of Homeland Security, she said.

FDA Seeks New Chief Information Officer As Privacy And Security Policies Get Overhaul

New CIO will help develop new policy to protect sensitive information at FDA, while also balancing individual privacy and security.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts